Clinical Trials Logo

Clinical Trial Summary

This study aimed to investigate the efficacy and safety of venetoclax combined with dexamethasone and etoposide as a salvage therapy for hemophagocytic lymphohistiocytosis.


Clinical Trial Description

Hemophagocytic lymphohistiocytosis (HLH) is a rare and aggressive disease with high mortality and poor prognosis. The HLH-94 and HLH-04 regimens are most commonly used, but approximately 30% of the patients remain unresponsive. Currently, there is no unified evidence-based salvage treatment. There is no unified salvage regimen. This study plans to enroll 20 patients with refractory and recurrent hemophagocytic lymphohistiocytosis. Subjects will receive venetoclax combined with dexamethasone and etoposide for 8 weeks.The safety was evaluated once a week, and the efficacy was evaluated once every 2 weeks. Overall response rate will be evaluated at 8 weeks. Patients were followed up every 3 months thereafter. ;


Study Design


Related Conditions & MeSH terms

  • Hemophagocytic Lymphohistiocytosis
  • Lymphohistiocytosis, Hemophagocytic

NCT number NCT05546060
Study type Interventional
Source Beijing Friendship Hospital
Contact Zhao Wang, MD
Phone 63138303
Email wangzhao@ccmu.edu.cn
Status Recruiting
Phase Phase 1
Start date July 1, 2022
Completion date October 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Recruiting NCT02912702 - L-DEP as an Initial Treatment for EBV-HLH Phase 3
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Completed NCT03510650 - Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
Completed NCT03259230 - Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Active, not recruiting NCT01494103 - Administration of Donor T Cells With the Caspase-9 Suicide Gene Phase 1
Recruiting NCT05164978 - DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Terminated NCT01547143 - Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis N/A
Active, not recruiting NCT00006056 - Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Recruiting NCT03795909 - Ruxolitinib Combined With Dexamethasone for HLH Phase 1/Phase 2
Recruiting NCT03533790 - DEP-Ru Regimen as a Salvage Therapy for HLH Phase 3
Not yet recruiting NCT05315336 - L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT04326348 - A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH) Phase 1
Recruiting NCT04551131 - Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Phase 1/Phase 2
Recruiting NCT05137522 - Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH N/A
Recruiting NCT04120090 - Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis Phase 3